Navigation Links
OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
Date:6/21/2010

versity of British Columbia and the Vancouver Prostate Centre, and were exclusively licensed to OncoGenex.

More information about OncoGenex is available at www.oncogenex.com.

OncoGenex' Forward Looking Statements

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning anticipated clinical and other product development activities, timing of these activities and projected cancer rates. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including, among others, the risk that the results of clinical trials may not be sustained in future clinical trials and the factors set forth in the Company's filings with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for fiscal year 2009. The Company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.


'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... As part of the long-term strategic approach, ... region during 2014 with potential global expansion. , "We ... DZS to manage our clinical trials globally and in ... R&D and President of SBI pharmaceuticals MENA, Dr. Riyadh ... a focus on utilizing eClinical software and flexible team ...
(Date:7/24/2014)... CA (PRWEB) July 24, 2014 ... reporting of molecular diagnostic test results. It also ... necessary for the validation and reporting of high ... Molecular diagnostics is a rapidly growing area of ... disease, genetic predisposition, cancer, and companion diagnostics in ...
(Date:7/23/2014)... YORK , July 24, 2014 ... Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX First ... "Immune" or "the Company"), announced a collaboration to ... pemphigoid last night at an event attended by ... interested parties. Lyfebulb is a health and wellness ...
(Date:7/23/2014)... Al Khaimah, United Arab Emirates (UAE) (PRWEB) July 23, ... firm Grace Century recently announced that its ... Dr. Jim Vaught , Ph.D. to its growing Advisory ... said, “We are very pleased to have Dr. Vaught ... with the scientific depth and expertise that Provia’s management ...
Breaking Biology Technology:SBI Pharmaceuticals Co. Ltd. Enters into Preferred Provider Agreement with DZS Clinical Services 2New DNA-barcode Patent Virtually Eliminates False Test Results and Sample Mix-up 2Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 2Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 3Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 4Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 5Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 2Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 3Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 4
... BRANFORD, Connecticut and STATE COLLEGE, Pennsylvania, May 9, ... Roche Company, and SoftGenetics announced today that the ... designed to provide users of 454 Sequencing Systems ... options provided by SoftGenetics NextGENe® software. ...
... JERICHO, N.Y., May 8, 2012 Health Care ... response to continued recent devastating natural and man-made ... the HCCS online training course, "Bioterrorism and Disaster ... (Logo:  http://photos.prnewswire.com/prnh/20061010/NYTU194LOGO ) "HCCS ...
... COPENHAGEN, May 8, 2012  Ekahau ... Location Systems (RTLS), today announced the launch of its newest ... Pager .  The B4 features an OLED text display and multiple ... to acknowledge receipt or to initiate calls and alarms. A unique ...
Cached Biology Technology:Roche 454 Life Sciences and SoftGenetics Sign Co-Promotion Agreement for Next-Gen Sequencing Software Tools 2Roche 454 Life Sciences and SoftGenetics Sign Co-Promotion Agreement for Next-Gen Sequencing Software Tools 3Free Disaster Preparedness Online Training Course 2Ekahau Launches Next Generation Wi-Fi RTLS Staff Badge and Pager 2Ekahau Launches Next Generation Wi-Fi RTLS Staff Badge and Pager 3
(Date:7/23/2014)... This news release is available in German . ... shape and stability to cells, drive metabolic processes and ... into complex three-dimensional shapes. Scientists at the Max Planck ... that proteins can be constructed of similar amino acid ... suggests that the proteins that exist today arose from ...
(Date:7/23/2014)... Innovative Networking in personalized cancer medicine, (the WIN consortium), ... Thomas Jefferson University will be one of ... this prestigious group in the Tri-State Area. The goal ... personalized medicine to the patient by forging collaborations between ... participation in the WIN consortium means Jefferson cancer patients ...
(Date:7/23/2014)... As local and national governments struggle to deal with ... now refining the picture of just how much there ... the ACS journal Environmental Science & Technology , ... that developed countries discard floods into just seven developing ... people who live there. , Knut Breivik and colleagues ...
Breaking Biology News(10 mins):Protein evolution follows a modular principle 2New partnership brings more personalized cancer treatment to Philadelphia 2
... 2011) -- In a biotechnological tour de force, Rice ... for rapidly converting simple glucose into biofuels and petrochemical ... , Rice,s team described how it reversed one of ... beta oxidation cycle -- to engineer bacteria that produce ...
... Cambridge, Mass. - August 10, 2011 - Between conception ... meters long, looping and coiling within the tiny abdomen. ... loops into the same formationhowever, until now, it has ... experimental observations, biological and biophysical manipulations, theory, and computation, ...
... Genetically engineered spider silk could help overcome a major ... according to a new study that reported development and successful ... ACS, journal Bioconjugate Chemistry . David Kaplan and ... genes to prevent or treat disease requires safe and ...
Cached Biology News:Metabolism in reverse: Making biofuels at full-throttle pace 2Gut coils with help from its elastic neighbor 2Gut coils with help from its elastic neighbor 3
... The epitope is specific for Kir2.1 ... other known protein.,SPECIES REACTIVITIES: The ... bovine, porcine and guinea pig. It ... mouse (17/19 residues) and chick (15/19 ...
Anti-20S proteasome subunits alpha 1, 2, 3, 5, 6 & 7, clone MCP231 Immunogen: Dinitrophenylated proteasomes Molecular Weight: 29 and 32 kDa....
Tight junctions are complexes of proteins that create intercellular boundaries between the plasma membrane domains of epithelial and endothelial cells. Antigen: Synthetic peptide corresponding to...
Biotin anti-mouse CD48...
Biology Products: